HomePeptide dosagesCagrilintide
Cagrilintide dosage: chart, reported range and vial math
Cagrilintide has been given once a week by injection under the skin in trials. The Phase 2 trial tested 0.3 mg to 4.5 mg a week and the Phase 3 trials used 2.4 mg. It is not approved in the US or Canada, so there is no label dose.
Legal status
US Not approved, in trials
Canada Not authorized
Checked 10 Oct 2026What is Cagrilintide?Cagrilintide dosage chart
Reported range, not a label dosePick your vial size. Each row shows the dose in milligrams or micrograms, the volume to draw and the mark on a U-100 syringe.
| When | Dose | Volume | Syringe units |
|---|---|---|---|
| Weeks 1 to 4 | 0.25 mg | 0.10 mL | 10 units |
| Weeks 5 to 8 | 0.5 mg | 0.20 mL | 20 units |
| Weeks 9 to 12 | 1 mg | 0.40 mL | 40 units |
| Weeks 13 to 16 | 1.7 mg | 0.68 mL | 68 units |
| Week 17 on | 2.4 mg | 0.96 mL | 96 units |
Source Reported step-up, not a label dose. The Phase 2 trial tested 0.3 to 4.5 mg a week and Phase 3 used 2.4 mg. Vial math is arithmetic.
Which syringe fits each dose
For the 5 mg vial at 2.5 mg/mL.
| Dose | Volume | Units | 0.3 mL syringe | 0.5 mL syringe | 1 mL syringe |
|---|---|---|---|---|---|
| 0.25 mg | 0.10 mL | 10 units | Yes | Yes | Yes |
| 0.5 mg | 0.20 mL | 20 units | Yes | Yes | Yes |
| 1 mg | 0.40 mL | 40 units | No | Yes | Yes |
| 1.7 mg | 0.68 mL | 68 units | No | No | Yes |
| 2.4 mg | 0.96 mL | 96 units | No | No | Yes |
How long a vial lasts
Whole doses in one vial. The row for the size picked above is marked.
| Vial | 0.25 mg | 0.5 mg | 1 mg | 1.7 mg | 2.4 mg |
|---|---|---|---|---|---|
| 5 mg vial | 20 doses | 10 doses | 5 doses | 2 doses | 2 doses |
| 10 mg vial | 40 doses | 20 doses | 10 doses | 5 doses | 4 doses |
How to mix a Cagrilintide vial
These steps are for the 5 mg vial picked in the chart. Change the size there and the amounts here change with it.
- Wash your hands. Wipe the stopper of the peptide vial and the water vial with an alcohol swab.
- Draw 2 mL of bacteriostatic water into a syringe.
- Push the needle through the stopper of the peptide vial and let the water run slowly down the glass, not straight onto the powder.
- Swirl the vial gently until the powder is gone. Do not shake it.
- Write the date and 2.5 mg/mL on the vial, then put it in the fridge.
| Vial | Bacteriostatic water | Concentration |
|---|---|---|
| 5 mg vial | 2 mL | 2.5 mg/mL |
| 10 mg vial | 2 mL | 5 mg/mL |
What Cagrilintide is
Cagrilintide is a long-acting amylin analogue under study as a once-weekly injection for weight management, on its own and combined with semaglutide. The combination is called CagriSema. [1]
Other names: NNC0174-0833.
How it has been given to people: subcutaneous injection, once weekly.
What to know before reading a dose
- Not an approved medicine in the US or Canada as of the check date. Every dose on record is a trial dose.
- FDA says cagrilintide cannot be used in compounding under federal law [7].
- The registry record for the phase 3 trial of cagrilintide alone [11] describes it as an investigational medicine that doctors may not yet prescribe.
- The large phase 3 results are for cagrilintide given with semaglutide. For cagrilintide alone the published human results found are the 26-week phase 2 trial.
Doses on record for Cagrilintide
Every dose below was given in a human study or printed on an approved label, and each links to its source. Doses set by body weight are left that way.
| From | Where it was used | Dose | How often | For how long | Source |
|---|---|---|---|---|---|
| Human study | Phase 2 dose-finding trial (NCT03856047), cagrilintide alone | 0.3 mg | once weekly | 26 weeks, including up to 6 weeks of dose escalation | [2] |
| Human study | Phase 2 dose-finding trial (NCT03856047), cagrilintide alone | 0.6 mg | once weekly | 26 weeks, including up to 6 weeks of dose escalation | [2] |
| Human study | Phase 2 dose-finding trial (NCT03856047), cagrilintide alone | 1.2 mg | once weekly | 26 weeks, including up to 6 weeks of dose escalation | [2] |
| Human study | Phase 2 dose-finding trial (NCT03856047), cagrilintide alone | 2.4 mg | once weekly | 26 weeks, including up to 6 weeks of dose escalation | [2] |
| Human study | Phase 2 dose-finding trial (NCT03856047), cagrilintide alone | 4.5 mg | once weekly | 26 weeks, including up to 6 weeks of dose escalation | [2] |
| Human study | Phase 3a REDEFINE 1, cagrilintide alone arm (302 participants) | 2.4 mg | once weekly | 68 weeks | [3] |
| Human study | Phase 3a REDEFINE 1, given together with semaglutide 2.4 mg (2108 participants) | 2.4 mg | once weekly | 68 weeks | [3] |
| Human study | Phase 3a REDEFINE 2, given together with semaglutide 2.4 mg | 2.4 mg | once weekly | 68 weeks | [4] |
What the evidence shows
Each finding is tagged by the kind of study it comes from. Human trials are listed first.
Randomized human trial
Cagrilintide alone, 26 weeks: weight loss was greater than placebo at every dose from 0.3 mg to 4.5 mg. The percentages are in the abstract and are not copied here (see not_found). [1]
Randomized human trial
With semaglutide, in adults without diabetes: mean weight change at 68 weeks was -20.4% on the combination against -3.0% on placebo. [3]
Randomized human trial
With semaglutide, in adults with type 2 diabetes: mean weight change at 68 weeks was -13.7% on the combination against -3.4% on placebo. [4]
Small human study
Single-dose studies found no clinically relevant change in cagrilintide blood levels in people with kidney or liver impairment. [6]
Side effects and warnings
Reported in human studies or on a label:
- Cagrilintide alone (phase 2): the most frequent adverse events were stomach and bowel problems such as nausea, constipation and diarrhea, and reactions where the injection was given. [1]
- With semaglutide (REDEFINE 1): stomach and bowel events affected 79.6% on the combination and 39.9% on placebo, mostly short-lived and mild to moderate. [3]
- With semaglutide in type 2 diabetes (REDEFINE 2): stomach and bowel events were reported by 72.5% on the combination and 34.4% on placebo. [4]
Cagrilintide has no approved label in the US or Canada for this use, so there is no official list of who should not use it, no interaction list and no missed-dose rule.
Storage
Keep an unmixed vial the way its label says. Once it is mixed, keep it in the fridge, do not freeze it, and write the mixing date on the vial.
Cagrilintide dosage questions
How many units is 0.5 mg of Cagrilintide from a 5 mg vial?
Mixed with 2 mL of bacteriostatic water, a 5 mg vial is 2.5 mg/mL. 0.5 mg is 0.20 mL, which is 20 units on a U-100 syringe.
How much water goes in a 5 mg Cagrilintide vial?
2 mL gives 2.5 mg/mL. At that strength the doses in the chart sit at 10, 20, 40, 68, 96 units on a U-100 syringe.
How many doses are in a 5 mg vial?
Whole doses in one vial: 20 at 0.25 mg, 10 at 0.5 mg, 5 at 1 mg, 2 at 1.7 mg, 2 at 2.4 mg.
Is Cagrilintide approved in the US?
Not FDA approved. FDA states cagrilintide is not a component of an FDA-approved drug and cannot be used in compounding.
Is Cagrilintide authorized in Canada?
No cagrilintide product is in the Health Canada Drug Product Database.
What is the half-life of Cagrilintide?
159 to 195 hours, about 6.6 to 8.1 days, measured in a phase 1b trial where it was given with semaglutide 2.4 mg.
What human dosing data is there for Cagrilintide?
Not an approved medicine in the US or Canada as of the check date. Every dose on record is a trial dose.
Sources
Each one was opened on 10 Oct 2026 and matched to the line it supports.
- Lau DCW et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet 2021. PubMed 34798060. Trial NCT03856047.
- ClinicalTrials.gov NCT03856047: Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity. clinicaltrials.gov. Trial NCT03856047.
- Garvey WT et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2025. PubMed 40544433. Trial NCT05567796.
- Davies MJ et al. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. N Engl J Med 2025. PubMed 40544432. Trial NCT05394519.
- Enebo LB et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet 2021. PubMed 33894838. Trial NCT03600480.
- Nielsen MJF et al. Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide. Clin Pharmacokinet 2026. PubMed 42228334.
- FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current as of 10/01/2026) fda.gov.
- Drugs@FDA via openFDA: search for active ingredient cagrilintide (no match) api.fda.gov.
- ClinicalTrials.gov search: studies with cagrilintide as an intervention (44 found) clinicaltrials.gov.
- Health Canada Drug Product Database: search for active ingredient cagrilintide (no match) health-products.canada.ca.
- ClinicalTrials.gov NCT07220642: Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide clinicaltrials.gov. Trial NCT07220642.
Looked for and not found
- No approved label anywhere, so no official contraindications, interaction list, missed-dose rule or storage instructions.
- Phase 2 weight-loss percentages by dose are not copied: the Lancet abstract [1] prints its decimals with a raised dot, which cannot be quoted word for word in an ASCII-only file. Read them at the PubMed link.
- The REDEFINE 1 abstract gives no result for the arm that took cagrilintide alone.
- The dose used in the cagrilintide-only phase 3 trial [11] is not stated in its registry record.
- Which regulators have received a CagriSema application, and when. Only the company pipeline page was found, and it does not say.
Change log
10 Oct 2026Page published. 11 sources checked. Vial math added for the 5 and 10 mg vials.
Related
Retatrutide dosageTirzepatide dosageSemaglutide dosageAOD-9604 dosage5-Amino-1MQ dosageWhat Cagrilintide isWeight loss and metabolicPeptide dosage chartDosage calculator
DosageFacts is an information site. It is not medical advice. Talk to a licensed professional before using any medication.